Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in children (6 to 11 years old) with severe persistent asthma.
Epistemonikos ID: 0502dcef1a1d790965de5319ff898252af98c665
First added on: May 11, 2024